公开(公告)号：WO2005067962A3

公开(公告)日：2005-09-22

申请号：PCT/EP2005000429

申请日：2005-01-12

Applicant: PULEVA BIOTECH SA ,  BARO RODRIGUEZ LUIS ,  BOZA PUERTA JULIO ,  FONOLLA JOYA JURISTO ,  GUADIX ESCOBAR EMILIA ,  JIMENEZ LOPEZ JESUS ,  LOPEZ-HUERTAS LEON EDUARDO ,  MARTINEZ-FEREZ ANTONIO ,  XAUS PEI JORDI

Inventor： BARO RODRIGUEZ LUIS ,  BOZA PUERTA JULIO ,  FONOLLA JOYA JURISTO ,  GUADIX ESCOBAR EMILIA ,  JIMENEZ LOPEZ JESUS ,  LOPEZ-HUERTAS LEON EDUARDO ,  MARTINEZ-FEREZ ANTONIO ,  XAUS PEI JORDI

IPC: A23C9/13 ,  A23C9/142 ,  A23C9/20 ,  A23C21/06 ,  A23L33/00 ,  A61K31/702 ,  A61K35/20 ,  A61K38/17 ,  A61K38/18 ,  A61K38/30

CPC classification number: A61K35/20 ,  A23C9/1307 ,  A23C9/1422 ,  A23C9/203 ,  A23C21/06 ,  A23C2210/202 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/702 ,  A61K38/1709 ,  A61K38/1808 ,  A61K38/1841 ,  A61K38/30 ,  A61K2300/00 ,  A23V2200/32 ,  A23V2200/3202 ,  A23V2250/28

Abstract: The invention relates to a composition obtained from goat milk comprising growth factors. This composition is characterised because these growth factor are in concentrations to be physiologically active and because these factors are selected from a list that comprises: Epidermal growth factor (EGF), transforming growth factor ß 2(TGFß2), insulin like growth factor type 1 (IGF-1) and anchored glycoprotein CD-14. The invention also relates to a process for obtaining the compositions of the invention, as well as a food product, a dietetic supplement or a nutritional supplement and their use in the prevention or treatment of diseases, as well as their use in cosmetics.

Abstract translation: 本发明涉及由含有生长因子的山羊奶得到的组合物。 该组合物的特征在于这些生长因子的浓度具有生理活性，并且因为这些因子选自包括以下的列表：表皮生长因子（EGF），转化生长因子β2（TGFβ2），胰岛素样生长因子1型 IGF-1）和锚定的糖蛋白CD-14。 本发明还涉及获得本发明组合物的方法，以及食品，饮食补充剂或营养补充剂及其在预防或治疗疾病中的用途以及它们在化妆品中的用途。

公开(公告)号：WO2005082927A3

公开(公告)日：2006-03-09

申请号：PCT/EP2005001992

申请日：2005-02-23

Applicant: PULEVA BIOTECH SA ,  GEERLINGS ARJIAN ,  HIDALGO ZARCO FERNANDO ,  BOZA PUERTA JULIO ,  JIMENEZ LOPEZ JESUS

Inventor： GEERLINGS ARJIAN ,  HIDALGO ZARCO FERNANDO ,  BOZA PUERTA JULIO ,  JIMENEZ LOPEZ JESUS

IPC: C07K7/06 ,  A23J3/34 ,  A23L1/305 ,  A61K38/00 ,  A61K38/06 ,  A61P9/12 ,  C07K5/08 ,  C07K5/083 ,  C07K5/093 ,  C07K5/10 ,  C07K5/103 ,  C07K14/47 ,  C12P21/06

CPC classification number: C07K14/4732 ,  A23J3/344 ,  A23L33/18 ,  A23L33/19 ,  A23V2002/00 ,  C07K5/0808 ,  C07K5/0819 ,  C07K5/1013 ,  C12P21/06 ,  A23V2200/326 ,  A23V2250/54246 ,  A23V2250/70 ,  A23V2250/7056

Abstract: The present invention refers to novel antihypertensive peptides which may be used as active ingredients in pharmaceutical preparations, dietary supplements, or as food ingredients. The peptides have/comprise the sequence YGPIPN or SLPE or SEPK (or fragments thereof) and are of between 3-8 residues in length.

Abstract translation: 本发明涉及可用作药物制剂，膳食补充剂或作为食品成分的活性成分的新型抗高血压肽。 肽具有/包含序列YGPIPN或SLPE或SEPK（或其片段），并且其长度为3-8个残基。

公开(公告)号：WO03082798A8

公开(公告)日：2004-04-29

申请号：PCT/ES0300152

申请日：2003-04-03

Applicant: PULEVA BIOTECH SA

Inventor： GEERLINGS ARJAN ,  LOPEZ-HUERTAS LEON EDUARDO ,  MORALES SANCHEZ JUAN CARLOS ,  BOZA PUERTA JULIO ,  JIMENEZ LOPEZ JESUS

IPC: A23C9/13 ,  A23C9/152 ,  A23C15/12 ,  A23L1/30 ,  A23L2/38 ,  A23L2/52 ,  A61K8/00 ,  A61K8/02 ,  A61K8/14 ,  A61K8/30 ,  A61K8/37 ,  A61K9/127 ,  A61K31/222 ,  A61K31/23 ,  A61K31/231 ,  A61K31/235 ,  A61P1/16 ,  A61P3/10 ,  A61P9/00 ,  A61P13/00 ,  A61P13/12 ,  A61P29/00 ,  A61Q17/04 ,  C07B61/00 ,  C07C67/08 ,  C07C69/007 ,  C07C69/017 ,  C07C69/025 ,  C07C69/18 ,  C07C69/28 ,  C07C69/30 ,  C07C69/533 ,  C07C69/58 ,  C07C69/587 ,  A61K7/42 ,  A61P3/02 ,  C07C69/16

CPC classification number: A23C9/13 ,  A23C9/152 ,  A23C15/12 ,  A23L33/105 ,  A23V2002/00 ,  A23V2250/2131 ,  A61K8/37 ,  A61Q17/04 ,  C07C69/007 ,  C07C69/017 ,  C07C69/28 ,  C07C69/30 ,  C07C69/533 ,  C07C69/58 ,  C07C69/587 ,  A23V2200/326 ,  A23V2250/2132

Abstract: The invention relates to phenolic compounds and the derivatives thereof which are represented by formula I, wherein: R1 and R2 are selected from OH, OCOalkyl or OCOalkenyl; R3 is H, OH, OCOalkyl or OCOalkenyl; the alkyl or alkenyl chains have between 2 and 22 carbon atoms; and at least one OCOalkyl or OCOalkenyl group is present in the structure. More specifically, the invention relates to the use of said compounds for the prevention or treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications. The invention also relates to compositions containing the above-mentioned compounds and to some novel phenolic compounds and the derivatives thereof.

Abstract translation: 本发明涉及由式I表示的酚类化合物及其衍生物，其中：R 1和R 2选自OH，OCO烷基或OCO链烯基; R3是H，OH，OCO烷基或OCO链烯基; 烷基或烯基链具有2至22个碳原子; 并且在结构中存在至少一个OCO烷基或OCO链烯基。 更具体地，本发明涉及所述化合物用于预防或治疗心血管，肝脏和肾脏疾病以及化妆品应用的用途。 本发明还涉及含有上述化合物和一些新型酚类化合物及其衍生物的组合物。

公开(公告)号：WO2004003235A3

公开(公告)日：2004-06-10

申请号：PCT/EP0306752

申请日：2003-06-26

Applicant: PULEVA BIOTECH SA ,  XAUS PEY JORDI ,  MARTIN JIMENEZ ROCIO ,  RODRIGUEZ GOMEZ JUAN MIGUEL ,  BOZA PUERTA JULIO ,  JIMENEZ LOPEZ JESUS

Inventor： XAUS PEY JORDI ,  MARTIN JIMENEZ ROCIO ,  RODRIGUEZ GOMEZ JUAN MIGUEL ,  BOZA PUERTA JULIO ,  JIMENEZ LOPEZ JESUS

IPC: A23C9/12 ,  A23C9/123 ,  A23C9/20 ,  A23L1/03 ,  A23L1/30 ,  A61K35/74 ,  A61K45/00 ,  A61P1/04 ,  A61P1/10 ,  A61P3/00 ,  A61P9/10 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/08 ,  C12N1/20 ,  C12Q1/04 ,  C12Q1/24

CPC classification number: C12R1/225 ,  A23C9/1232 ,  A23C9/1234 ,  A23C9/206 ,  A23L29/065 ,  A23L33/135 ,  A23Y2220/77 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  C12R1/25 ,  Y10S435/853

Abstract: The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides new Lactobacillus strains, which are: CECT5711 (Lactobacillus coryniformis), CECT5713 (Lactobacillus salivarius subsp. salivarius), CECT5714: (Lactobacillus gasseri, formerly L. acidophilus), CETC5715: (Lactobacillus gasseri), and CECT5716: (Lactobacillus fermentum); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.

Abstract translation: 本发明涉及用于选择新益生菌菌株的新型方法，其包括以下步骤：a）选择能够在母乳和/或羊水中存活的非致病性菌株，和b）选择非致病性菌株， 能够在健康个体口服摄入后转移到母乳和/或羊水中的致病性菌株，而不粘附除粘液以外的其他内部器官。 本发明还提供了新的乳酸杆菌菌株，其为CECT5711（棒状乳杆菌），CECT5713（唾液乳杆菌唾液亚种），CECT5714 :(加氏乳杆菌，前身为嗜酸乳杆菌），CETC5715 :(加氏乳杆菌）和CECT5716 :(乳杆菌 发酵）; 并指其用于预防或治疗消化，感染，神经退行性疾病和免疫相关疾病如变态反应或炎性疾病。